Shots:
- BioCryst Pharmaceuticals has entered into a license agreement with an Irish affiliate of Neopharmed Gentili, granting the latter exclusive rights to commercialize navenibart for hereditary angioedema (HAE) in the EU
- As per the deal, BioCryst will receive $70M upfront & up to $275M in regulatory & sales milestone payments as well as tiered royalties on net sales ranging from 18% to 30%
- Navenibart, a long-acting plasma kallikrein inhibitor, is being evaluated in a P-III program in hereditary angioedema, which is on track to support regulatory filing by the end of 2027
Ref: Globenewswire | Image: BioCryst & Neopharmed Gentili |Press Release
Related News: BioCryst to Acquire Astria Therapeutics in ~$700M Cash-and-Stock Transaction
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
